Paraoxonase status and plasma butyrylcholinesterase activity in chlorpyrifos manufacturing workers

Journal of Exposure Science and Environmental Epidemiology

Volumn 20, Issue 1, 2010, Pages 79-89

  Albers, James W ^a   Garabrant, David H ^b   Berent, Stanley ^c   Richardson, Rudy J ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Butyrylcholinesterase; Chlorpyrifos; Chlorpyrifosoxonase; Paraoxonase; PON1

Indexed keywords

ADOLESCENT; ADULT; AGED; ARYLDIALKYLPHOSPHATASE; BUTYRYLCHOLINESTERASE; CHLORPYRIFOS; CHOLINESTERASE INHIBITORS; FEMALE; HUMANS; INSECTICIDES; MALE; MANUFACTURED MATERIALS; MIDDLE AGED; OCCUPATIONAL EXPOSURE; PYRIDONES; RISK ASSESSMENT; TIME FACTORS; YOUNG ADULT;

3,5,6-TRICHLORO-2-PYRIDINOL; ARYLDIALKYLPHOSPHATASE; CHLORPYRIFOS; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; INSECTICIDE; PYRIDONE DERIVATIVE;

ADOLESCENT; ADULT; ADVERSE EFFECTS; AGED; ANALYSIS; BLOOD; DEVICE MATERIAL; FEMALE; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; OCCUPATIONAL EXPOSURE; RISK ASSESSMENT; TIME FACTOR; TOXICITY; YOUNG ADULT;

EID: 73649131634     PISSN: 15590631     EISSN: 1559064X     Source Type: Journal    
DOI: 10.1038/jes.2009.9     Document Type: Article

References (39)

1. Albers J.W., Berent S., Garabrant D.H., Giordani B., Schweitzer S., Garrison R.P., and Richardson R.J. The effects of occupational exposure to chlorpyrifos on the neurological examination of central nervous system function: A prospective cohort study. J Occup Environ Med 2004a: 46: 367-378. (Pubitemid 38469014)
2. Albers J.W., Garabrant D.H., Mattsson J.L., Burns C.J., Cohen S.S., Sima C., Garrison R.P., et al. Dose-effect analyses of occupational chlorpyrifos exposure and peripheral nerve electrophysiology. Toxicol Sci 2007: 97: 196-204.
3. Albers J.W., Garabrant D.H., Schweitzer S.J., Garrison R.P., Richardson R.J., and Berent S. The effects of occupational exposure to chlorpyrifos on the peripheral nervous system: A prospective cohort study. Occup Environ Med 2004b: 61: 201-211.
4. Alcantara V.M., Chautard-Freire-Maia E.A., Scartezini M., Cerci M.S., Braun-Prado K., and Picheth G. Butyrylcholinesterase activity and risk factors for coronary artery disease. Scand J Clin Lab Invest 2002: 62: 399-404.
5. Amitai G., Gaidukov L., Adani R., Yishay S., Yacov G., Kushnir M., Teitlboim S., et al. Enhanced stereoselective hydrolysis of toxic organophosphates by directly evolved variants of mammalian serum paraoxonase. FEBS J 2006: 273: 1906-1919.
6. Aviram M., Billecke S., Sorenson R., Bisgaier C., Newton R., Rosenblat M., Erogul J., et al. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol 1998: 18: 1617-1624.
7. Billecke S., Draganov D., Counsell R., Stetson P., Watson C., Hsu C., and La Du B.N. Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos 2000: 28: 1335-1342.
8. Burns C.J., Garabrant D.H., Albers J.W., Berent S., Giordani B., Haidar S., and Garrison R.P., et al. Chlorpyrifos exposure and biological monitoring among manufacturing workers. Occup Environ Med 2006: 63: 218-220.
9. Calderon-Margalit R., Adler B., Abramson J.H., Gofin J., and Kark J.D. Butyrylcholinesterase activity, cardiovascular risk factors, and mortality in middle-aged and elderly men and women in Jerusalem. Clin Chem 2006: 52: 845-852.
10. Catano H.C., Cueva J.L., Cardenas A.M., Izaguirre V., Zavaleta A.I., Carranza E., and Hernandez A.F. Distribution of paraoxonase-1 gene polymorphisms and enzyme activity in a Peruvian population. Environ Mol Mutagen 2006: 47: 699-706.
11. Cattozzo G., Franzini C., and Rettondini M. Dibucaine number measured with the Ektachem. Clin Chem 1993: 39: 1545-1546.
12. Costa L.G., Cole T.B., and Furlong C.E. Polymorphisms of paraoxonase (PON1) and their significance in clinical toxicology of organophosphates. J Toxicol Clin Toxicol 2003: 41: 37-45.
13. Costa L.G., Cole T.B., Vitalone A., and Furlong C.E. Measurement of paraoxonase (PON1) status as a potential biomarker of susceptibility to organophosphate toxicity. Clin Chim Acta 2005: 352: 37-47.
14. Costa L.G., Li W.F., Richter R.J., Shih D.M., Lusis A., and Furlong C.E. The role of paraoxonase (PON1) in the detoxication of organophosphates and its human polymorphism. Chem Biol Interact 1999: 119-120: 429-438.
15. Davies H.G., Richter R.J., Keifer M., Broomfield C.A., Sowalla J., and Furlong C.E. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet 1996: 14: 334-336.
16. Ellman G.L., Courtney K.D., Andres Jr V., and Featherstone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961: 31: 1117-1121.
17. Fu A.L., Wang Y.X., and Sun M.J. Naked DNA prevents soman intoxication. Biochem Biophys Res Commun 2005: 328: 901-905.
18. Furlong C.E. PON1 status and neurologic symptom complexes in Gulf War veterans. Genome Res 2000: 10: 153-155.
19. Furlong C.E., Holland N., Richter R.J., Bradman A., Ho A., and Eskenazi B. PON1 status of farmworker mothers and children as a predictor of organophosphate sensitivity. Pharmacogenet Genomics 2006: 16: 183-190.
20. Furlong C.E., Li W.F., Brophy V.H., Jarvik G.P., Richter R.J., Shih D.M., Lusis A.J., et al. 2000a The PON1 gene and detoxication. Neurotoxicology 21: 581-587.
21. Furlong C.E., Li W.F., Richter R.J., Shih D.M., Lusis A.J., Alleva E., and Costa L.G. Genetic and temporal determinants of pesticide sensitivity: role of paraoxonase (PON1). Neurotoxicology 2000b: 21: 91-100.
22. Furlong C.E., Richter R.J., Seidel S.L., Costa L.G., and Motulsky A.G. Spectrophotometric assays for the enzymatic hydrolysis of the active metabolites of chlorpyrifos and parathion by plasma paraoxonase/arylesterase. Anal Biochem 1989: 180: 242-247.
23. Furlong C.E., Richter R.J., Seidel S.L., and Motulsky A.G. Role of genetic polymorphism of human plasma paraoxonase/arylesterase in hydrolysis of the insecticide metabolites chlorpyrifos oxon and paraoxon. Am J Hum Genet 1988: 43: 230-238.
24. Garabrant D.H., Aylward L.L., Chen Q., Timchalk C., Burns C.J., Hays S.M., and Albers J.W. Cholinesterase inhibition in chlorpyrifos workers: Characterization of biomarkers of exposure and response in relation to urinary TCPy. J Expo Sci Environ Epidemiol 2009 (in press; doi:10.1038/jes.2008.51).
25. Haley R.W., Billecke S., and La Du B.N. Association of low PON1 type Q (type A) arylesterase activity with neurologic symptom complexes in Gulf War veterans. Toxicol Appl Pharmacol 1999: 157: 227-233.
26. Hassett C., Richter R.J., Humbert R., Chapline C., Crabb J.W., Omiecinski C.J., and Furlong C.E. Characterization of cDNA clones encoding rabbit and human serum paraoxonase: the mature protein retains its signal sequence. Biochemistry 1991: 30: 10141-10149.
27. Hegele R.A. Paraoxonase genes and disease. Ann Med 1999: 31: 217-224.
28. Hernandez A.F., Amparo G.M., Perez V., Garcia-Lario J.V., Pena G., Gil F., Lopez O., et al. Influence of exposure to pesticides on serum components and enzyme activities of cytotoxicity among intensive agriculture farmers. Environ Res 2006: 102: 70-76.
29. Hernandez A.F., Gonzalvo M.C., Gil F., Rodrigo L., Villanueva E., and Pla A. Distribution profiles of paraoxonase and cholinesterase phenotypes in a Spanish population. Chem Biol Interact 1999: 119-120: 201-209.
30. Holland N., Furlong C., Bastaki M., Richter R., Bradman A., Huen K., Beckman K., et al. Paraoxonase polymorphisms, haplotypes, and enzyme activity in Latino mothers and newborns. Environ Health Perspect 2006: 114: 985-991.
31. Jarvik G.P., Jampsa R., Richter R.J., Carlson C.S., Rieder M.J., Nickerson D.A., and Furlong C.E. Novel paraoxonase (PON1) nonsense and missense mutations predicted by functional genomic assay of PON1 status. Pharmacogenetics 2003: 13: 291-295.
32. Jarvik G.P., Rozek L.S., Brophy V.H., Hatsukami T.S., Richter R.J., Schellenberg G.D., and Furlong C.E. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype. Arterioscler Thromb Vasc Biol 2000: 20: 2441-2447.
33. Khersonsky O., and Tawfik D.S. Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry 2005: 44: 6371-6382.
34. Lee B.W., London L., Paulauskis J., Myers J., and Christiani D.C. Association between human paraoxonase gene polymorphism and chronic symptoms in pesticide-exposed workers. J Occup Environ Med 2003: 45: 118-122.
35. Li W.F., Costa L.G., and Furlong C.E. Serum paraoxonase status: A major factor in determining resistance to organophosphates. J Toxicol Environ Health 1993: 40: 337-346.
36. LiW.F., Costa L.G., RichterR.J., Hagen T., ShihD.M., Tward A., Lusis A.J., et al. Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds. Pharmacogenetics 2000: 10: 767-779.
37. Richter R.J., and Furlong C.E. Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics 1999: 9: 745-753.
38. Souza R.L., Fadel-Picheth C., Allebrandt K.V., Furtado L., and Chautard-Freire-Maia E.A. Possible influence of BCHE locus of butyrylcholinesterase on stature and body mass index. Am J Phys Anthropol 2005: 126: 329-334.
39. Timchalk C., Kousba A., and Poet T.S. Monte Carlo analysis of the human chlorpyrifos-oxonase (PON1) polymorphism using a physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model. Toxicol Lett 2002: 135: 51-59.